Hightide Therapeutics Inc (HK:2511)
:2511
Want to see HK:2511 full AI Analyst Report?
Total Valuation
Hightide Therapeutics Inc has a market cap or net worth of HK$2.05B. The enterprise value is HK$1.96B.
Market CapHK$2.05B
Enterprise ValueHK$1.96B
Share Statistics
Hightide Therapeutics Inc has 571,325,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding571,325,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hightide Therapeutics Inc’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -44.27%.
Return on Equity (ROE)-0.78
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-44.27%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee0.00
Profits Per Employee-3.31M
Employee Count70
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Hightide Therapeutics Inc is ―. Hightide Therapeutics Inc’s PEG ratio is 0.13.
PE Ratio―
PS Ratio0.00
PB Ratio4.14
Price to Fair Value4.14
Price to FCF-7.61
Price to Operating Cash Flow-41.44
PEG Ratio0.13
Income Statement
In the last 12 months, Hightide Therapeutics Inc had revenue of 0.00 and earned -238.63M in profits. Earnings per share was -0.49.
Revenue0.00
Gross Profit0.00
Operating Income-217.78M
Pretax Income-225.88M
Net Income-238.63M
EBITDA-217.78M
Earnings Per Share (EPS)-0.49
Cash Flow
In the last 12 months, operating cash flow was -107.85M and capital expenditures -4.59M, giving a free cash flow of -112.44M billion.
Operating Cash Flow-107.85M
Free Cash Flow-112.44M
Free Cash Flow per Share-0.20
Dividends & Yields
Hightide Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change78.54%
50-Day Moving Average2.89
200-Day Moving Average3.17
Relative Strength Index (RSI)68.37
Average Volume (3m)1.41M
Important Dates
Hightide Therapeutics Inc upcoming earnings date is Sep 1, 2026, Before Open (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
Hightide Therapeutics Inc as a current ratio of 5.41, with Debt / Equity ratio of 41.32%
Current Ratio5.41
Quick Ratio5.41
Debt to Market Cap0.09
Net Debt to EBITDA0.48
Interest Coverage Ratio-94.57
Taxes
In the past 12 months, Hightide Therapeutics Inc has paid 213.33K in taxes.
Income Tax213.33K
Effective Tax Rate>-0.01
Enterprise Valuation
Hightide Therapeutics Inc EV to EBITDA ratio is -5.35, with an EV/FCF ratio of -6.98.
EV to Sales0.00
EV to EBITDA-5.35
EV to Free Cash Flow-6.98
EV to Operating Cash Flow-6.98
Balance Sheet
Hightide Therapeutics Inc has HK$467.01M in cash and marketable securities with HK$99.47M in debt, giving a net cash position of HK$367.53M billion.
Cash & Marketable SecuritiesHK$467.01M
Total DebtHK$99.47M
Net CashHK$367.53M
Net Cash Per ShareHK$0.64
Tangible Book Value Per ShareHK$0.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Hightide Therapeutics Inc is HK$5.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$5.80
Price Target Upside90.16% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast39.48%